For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
Tesamorelin (EGRIFTA) is the only FDA-approved GHRH analogue, approved since 2010 for HIV-associated lipodystrophy, with a March 2025 approval of the once-weekly EGRIFTA WR formulation. Two Phase 3 RCTs (n=806) established 15 to 20% selective visceral fat reduction. NIH-funded off-label research shows compelling MASLD liver fat reduction (35% complete resolution at 12 months), cognitive function improvements, and skeletal muscle benefits.
Tesamorelin holds full FDA approval since November 2010 for reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy -- making it one of only two compounds in this research series with a long-standing FDA approval (alongside SS-31's 2025 Barth syndrome approval). It is classified as a biologic (Biologics License Application) and marketed under the brand names EGRIFTA, EGRIFTA SV, and as of March 2025, EGRIFTA WR (the new F8 once-weekly formulation approved March 2025).
The approved indication is narrow and specific: HIV-associated lipodystrophy. Substantial off-label research conducted at major academic institutions (Massachusetts General Hospital, NIH) explores tesamorelin's effects on liver disease, cognition, cardiovascular risk, and skeletal muscle. These off-label applications have varying levels of human evidence and are not covered by the FDA approval.
A key mechanistic conflict noted in the prescribing information: tesamorelin should not be combined with CJC-1295 or ipamorelin, as combining GHRH-axis compounds with GHS-R1a agonists produces unvalidated synergistic GH stimulation that may exceed physiological parameters. Clinicians using tesamorelin off-label alongside other GH-axis compounds should note this.
Tesamorelin is a synthetic analogue of human GHRH in which a trans-3-hexenoic acid moiety has been anchored at the N-terminus of the 44 amino acid sequence of human GHRH, resulting in enhanced stability in serum compared to natural human GHRH. This structural modification addresses a key limitation of natural GHRH and sermorelin, which degrade rapidly in circulation. The drug maintains a pulsatile pattern of GH release that more closely mimics physiological secretion compared to exogenous GH administration.
Tesamorelin stimulates natural GH production by binding to GHRH receptors on pituitary somatotrophs. The trans-3-hexenoic acid modification provides enhanced metabolic stability over native GHRH through improved resistance to dipeptidyl peptidase IV (DPP-IV) degradation, resulting in more sustained receptor activation. GH-mediated lipolysis is particularly active in visceral fat depots because these adipocytes have the highest density of GH receptors and are most responsive to GH-stimulated hormone-sensitive lipase activation. This depot selectivity is the mechanistic basis for tesamorelin's specific action on visceral fat while largely sparing subcutaneous fat.
The March 2025 FDA approval of the EGRIFTA WR (F8) once-weekly formulation represents the most recent regulatory milestone -- not a new indication but a meaningful formulation improvement that reduces the daily reconstitution burden to once-weekly while maintaining identical biological activity.
Tesamorelin functions as a GHRH receptor agonist, binding to and activating the same receptors that endogenous GHRH targets on the anterior pituitary gland. The trans-3-hexenoic acid N-terminal modification enhances the peptide's stability and DPP-IV resistance without altering the fundamental mechanism: stimulating the anterior pituitary to produce and release GH in a natural, pulsatile pattern that preserves the body's normal somatostatin feedback mechanisms.
The specificity of tesamorelin's effect on visceral rather than subcutaneous fat is well-documented across Phase 3 trials. Visceral adipose tissue is metabolically distinct -- it drains directly into the portal circulation and contributes disproportionately to hepatic insulin resistance, inflammatory cytokine production, and cardiovascular risk. By selectively reducing this depot via GH-mediated lipolysis, tesamorelin improves the cardiometabolic profile beyond what would be expected from total fat loss alone.
The cAMP-PKA pathway in somatotroph cells is activated with improved resistance to DPP-IV degradation, resulting in more sustained receptor activation than native GHRH. Like sermorelin, the preserved somatostatin feedback provides a physiological ceiling preventing supraphysiological GH exposure.
At week 26, VAT decreased significantly in tesamorelin-treated patients (-24 cm2 vs. +2 cm2 for placebo, treatment effect -15.4%, P<0.001). No significant changes were observed in abdominal subcutaneous adipose tissue. Treatment resulted in significant decreases in triglycerides (treatment effect -12.3%) and cholesterol-to-HDL ratio (treatment effect -7.2%) versus placebo. Tesamorelin improved body image scores and physician and patient ratings of belly profile. At week 52, decreases in VAT (-17.5%), waist circumference (-3.4 cm), and triglycerides (-48 mg/dl) were maintained.
Across all pivotal trials, the LS mean differences of tesamorelin versus placebo were -19.6% (95% CI: -23.7% to -15.3%) in LIPO-010, and -11.7% (95% CI: -16.2% to -7.1%) in CTR-1011.
Among participants on integrase inhibitor-based regimens in the modern-ART cohort (Russo 2024), tesamorelin led to significant declines in visceral fat (median -25 cm2 versus +14 cm2 for placebo, P=0.001), with no change in subcutaneous fat compared to placebo. Tesamorelin also led to declines in hepatic fat fraction and trunk-to-appendicular fat ratio, confirming efficacy in the era of current antiretroviral therapy.
This is tesamorelin's most robustly validated application -- the only indication supported by two Phase 3 RCTs totaling over 800 patients, a 52-week pooled analysis, and multiple additional confirmatory studies. The 15 to 20% visceral fat reduction is highly selective (subcutaneous fat largely preserved), metabolically significant, and durable over 52 weeks. The 2024 INSTI-era data confirms efficacy in patients on modern antiretroviral regimens, resolving an important clinical question since the Phase 3 trials predated integrase inhibitor dominance.
Tesamorelin reduced hepatic fat by a relative 40% among people living with HIV with abdominal fat accumulation, compared to a 27% increase in the placebo arm. Tesamorelin responders had concurrent improvements in HbA1c, hepatic transaminases, and adiponectin.
In the multicentre Stanley 2020 Lancet HIV trial (n=61, 12 months): 35% of patients receiving tesamorelin had less than 5% steatosis at 12 months, no longer meeting criteria for MASLD. Tesamorelin reduced liver fat content and prevented liver inflammation and fibrosis progression. Tesamorelin has been associated with downregulation of immune system activation in liver tissue.
The liver fat data is among tesamorelin's most clinically compelling findings beyond its approved indication. A 40% relative reduction in liver fat with 35% of treated patients achieving complete MASLD resolution in 12 months, accompanied by hepatic transcriptomic changes and biomarkers of inflammation and fibrosis prevention, is a substantial result. A Phase II trial in non-HIV NAFLD patients is underway (NCT03375788), which would be transformational if positive -- it could broaden tesamorelin's applicability to the far larger general MASLD population.
In the Baker 2012 study, subjects received either 1 mg of tesamorelin or placebo over 20 weeks and were measured on executive function, verbal memory, and visual memory. Tesamorelin demonstrated favorable effects on cognition in both adults with mild cognitive impairment and healthy older adults. Adverse events were reported in 68% of tesamorelin subjects, but the events were mild -- primarily localized skin reactions and increased joint pain.
In people with HIV who are virally suppressed with antiretroviral therapy, abdominal obesity is linked to neurocognitive impairment, potentially due to visceral adiposity, inflammation, and reduced IGF-1. Tesamorelin reduces abdominal obesity and increases IGF-1, suggesting it might mitigate neurocognitive impairment in people with HIV.
The 2012 cognitive function RCT is a genuinely important finding -- a properly designed trial in both MCI patients and healthy older adults showing tesamorelin improved executive function and verbal memory over 20 weeks. The mechanistic pathway (GHRH → GH → IGF-1 → neurotrophic effects in hippocampus and prefrontal cortex) is well-established in neuroendocrinology. This represents one of the most validated cognitive function signals in this category, on par with ARA 290's sarcoidosis neuropathy data in terms of being a properly controlled human RCT.
Tesamorelin was associated with significantly greater increases in density of four truncal muscle groups and the lean anterolateral/abdominal and rectus muscles compared to placebo. Significant increases were also seen in total area of the rectus and psoas muscles, and in the lean muscle area of all four truncal muscle groups. Among those with clinically significant VAT decrease on treatment, tesamorelin was effectively increasing skeletal muscle area and density.
The dual effect on body composition -- simultaneously reducing visceral fat and improving skeletal muscle quality and quantity -- is pharmacologically rare. Most anti-obesity treatments carry the risk of lean mass loss. Tesamorelin achieves the opposite: VAT reduction while preserving or improving muscle through GH/IGF-1-mediated anabolic effects.
Clinically meaningful secondary finding from Phase 3 trial data. The simultaneous improvement in both fat and muscle quality is a significant advantage over non-GH-axis anti-obesity approaches. For the aging HIV-positive population -- who experience accelerated sarcopenia -- this dual benefit is particularly relevant. An ongoing trial examining tesamorelin combined with exercise (NCT06554717) is designed to assess whether the combination amplifies muscle and functional benefits beyond each intervention alone.
Treatment with tesamorelin resulted in significant decreases in triglycerides (-37 mg/dL vs. +6 mg/dL for placebo, P<0.001; treatment effect -12.3%) and cholesterol-to-HDL ratio (treatment effect -7.2%) versus placebo.
A 2025 study in Open Forum Infectious Diseases concluded that tesamorelin can lead to a significant reduction in cardiovascular disease risk among people with HIV, a population whose likelihood of a cardiovascular event is twice as high compared to the general population.
Note: the prescribing information specifically states that long-term cardiovascular safety has not been established.
Cardiovascular risk marker improvements (triglycerides, cholesterol/HDL ratio) are consistently documented across Phase 3 data and represent clinically meaningful secondary benefits. The 2025 analysis showing improved cardiovascular risk prediction scores is an important addition. However, no hard cardiovascular endpoint data (MACE reduction) exists, and long-term cardiovascular safety remains formally unestablished in the prescribing information.
No significant differences were observed between groups in relative insulin response over the 12-week treatment period. At Week 12, fasting glucose, HbA1c, and overall diabetes control were not significantly different between groups. This trial was specifically designed to address the concern that GH stimulation might worsen glycemic control in T2D patients -- a concern arising from GH's known glucose counter-regulatory effects. The finding that tesamorelin at therapeutic doses did not significantly worsen glycemic control in T2D patients was a critical safety demonstration.
A reassuring safety study rather than a therapeutic efficacy claim. T2D patients represent a significant proportion of the overweight/metabolic syndrome population who might benefit from visceral fat reduction, so demonstrating acceptable glycemic safety in this population was an important regulatory and clinical milestone.
FDA-approved at 2mg for HIV lipodystrophy (Egrifta).
Tesamorelin has the most robust validated human dosing protocol of any GHRH-axis compound in this research series, established through FDA approval. The 2 mg once-daily SubQ protocol (or equivalent once-weekly EGRIFTA WR) is the reference standard. Off-label applications (MASLD, cognitive aging, sarcopenia) use this approved dosing. Glucose monitoring is recommended per prescribing information. Contraindicated in active malignancy. Retinopathy surveillance required in diabetic patients.
Tesamorelin vs. sermorelin (most direct comparison): Both are GHRH-axis compounds targeting the same receptor. Tesamorelin's trans-3-hexenoic acid modification extends duration sufficiently to produce sustained VAT reduction that built its FDA approval. Sermorelin's 11 to 12 minute half-life preserves the episodic pulsatile rhythm associated with cognitive and sleep benefits. Tesamorelin superseded sermorelin in HIV lipodystrophy. Sermorelin may retain advantages in applications favoring discrete GH pulses.
Tesamorelin vs. retatrutide (evidence quality comparison): Both have robust Phase 3 human data and institutional backing. Tesamorelin has 15 years of post-approval real-world experience in a specific population; retatrutide is addressing a far larger general obesity population with greater weight loss magnitude. Tesamorelin's visceral fat selectivity is mechanistically distinct from retatrutide's broad metabolic effects across GLP-1, GIP, and glucagon pathways.
Tesamorelin vs. ipamorelin (mechanistic conflict note): These compounds act via different receptors (GHRH-R vs. GHS-R1a). While they can theoretically be combined for synergistic GH stimulation (the CJC-1295/ipamorelin rationale applies similarly here), the prescribing information cautions against unvalidated combination use. Clinicians should not assume that combining tesamorelin with ghrelin mimetics is validated or safe.
Hypersensitivity reactions occurred in 4% of patients treated with EGRIFTA in clinical trials, including pruritus, erythema, flushing, urticaria, and rash. Injection site reactions occurred in 25% of EGRIFTA-treated patients versus 14% in placebo-treated patients during the first 26 weeks.
Patients with and without anti-tesamorelin IgG antibodies had similar mean reductions in visceral adipose tissue and IGF-1 response. In a group of patients who had antibodies after 26 weeks (56%) and were reassessed 6 months later after stopping treatment, 18% were still positive. No potential mutagenicity was revealed in a battery of tests.
Key safety considerations from the prescribing information: contraindication in active malignancy (IGF-1 elevation is a class concern); monitoring for glucose intolerance (GH counter-regulation); retinopathy surveillance (EGRIFTA WR prescribing information specifically notes monitoring at regular intervals for potential development or worsening of retinopathy); avoidance in pregnancy (Pregnancy Category C; hydrocephaly in rats at high doses).
The antibody development finding (56% develop IgG antibodies) is notable but clinically non-consequential -- antibody-positive and antibody-negative patients have equivalent efficacy outcomes. Long-term cardiovascular safety has not been formally established and the prescribing information includes a statement advising consideration of risk-benefit if no VAT reduction is achieved.
Tesamorelin sits in a unique position within this research series: an approved pharmaceutical with 15 years of post-approval real-world use and a growing body of NIH-funded off-label research. Like retatrutide, it is a regulated pharmaceutical product with robust Phase 3 human data. Unlike retatrutide (still investigational), tesamorelin has 15 years of post-approval use allowing real-world safety and effectiveness data to accumulate.
Its most distinctive scientific characteristic is the selectivity of visceral fat reduction. While retatrutide, GLP-1 agonists, and other weight loss agents broadly reduce body mass, tesamorelin specifically targets the deep abdominal visceral depot while leaving subcutaneous fat largely intact. This selectivity arises from the high GH receptor density in visceral adipocytes and represents a mechanistically differentiated therapeutic approach.
The ongoing Phase II non-HIV MASLD trial (NCT03375788) represents tesamorelin's most important near-term development pathway. If positive, it would open an indication relevant to hundreds of millions of patients globally with fatty liver disease, substantially expanding the clinical and commercial reach of an already-approved, well-characterized drug.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use